ArticleClinical and translational gastroenterology2018
Gut Microbiota-Based Therapies for Irritable Bowel Syndrome.
Article in Clinical and translational gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Adjunctive treatment with probiotics partially alleviates symptoms and reduces inflammation in patients with irritable bowel syndrome.European journal of nutrition · 2021Trial
- Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults.Scientific reports · 2019Trial
- A novel synbiotic (SCM06) for anxiety and sensory hyperresponsiveness in children with autism spectrum disorder: an open-label pilot study.NPJ biofilms and microbiomes · 2026Article
- Inflammatory Prostatitis Plus IBS-D Subtype and Correlation with Immunomodulating Agent Imbalance in Seminal Plasma: Novel Combined Treatment.Diseases (Basel, Switzerland) · 2024Article
- Effectiveness of Probiotic Use in Alleviating Symptoms of Irritable Bowel Syndrome: A Systematic Review.Cureus · 2024Review
- Review
- Assessing the relationship between gut microbiota and irritable bowel syndrome: a two-sample Mendelian randomization analysis.BMC gastroenterology · 2023Article
- Gastrointestinal problems, mechanisms and possible therapeutic directions in Gulf war illness: a mini review.Military Medical Research · 2021Review
- Global research trends in the microbiome related to irritable bowel syndrome: A bibliometric and visualized study.World journal of gastroenterology · 2021Article
- Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort.Gut microbes · 2020Article
- Effects of Novel Probiotics in a Murine Model of Irritable Bowel Syndrome.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2020Article
- Metabolic Trifecta After Pancreatitis: Exocrine Pancreatic Dysfunction, Altered Gut Microbiota, and New-Onset Diabetes.Clinical and translational gastroenterology · 2019Article
- Gastrointestinal Dysmotility in MNGIE: from thymidine phosphorylase enzyme deficiency to altered interstitial cells of Cajal.Orphanet journal of rare diseases · 2019Review
- Article
- Influence of Early Life, Diet, and the Environment on the Microbiome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Review
- (Patho-)Physiology of NaFrontiers in physiology · 2019Review
- The Potential Role of Gut Mycobiome in Irritable Bowel Syndrome.Frontiers in microbiology · 2019Review
- A Retrospective Study on Dietary FODMAP Intake in Celiac Patients Following a Gluten-Free Diet.Nutrients · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a common, heterogeneous disorder characterized by abdominal pain associated with changes in bowel habits. The pathogenesis of IBS is multifactorial and may relate to alterations in the gut microbiota, changes in visceral sensation and motility, and genetic and environmental factors. Administration of systemic antibiotics may increase the risk of IBS by altering gastrointestinal homeostasis. Therapeutic interventions for IBS with diarrhea that are thought to target alterations in the gut microbiota include the nonsystemic antibiotic rifaximin, the medical food serum-derived bovine immunoglobulin, prebiotics, probiotics, and dietary modification. SYN-010 is a modified-release statin formulation that reduces methane production by Methanobrevibacter smithii and is currently in development for the treatment of patients with constipation-predominant IBS. Use of these interventions in the management of patients with IBS may function to restore a healthy gut microbiota and ameliorate symptoms of IBS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.